What does the 'Cochrane database of systematic reviews' tell us about hemophilia?

What does the 'Cochrane database of systematic reviews' tell us about hemophilia? Expert Rev Hematol. 2019 Oct 14;:1-4 Authors: Rodriguez-Merchan EC Abstract Introduction: The purpose of this article is to review which data about hemophilia are currently provided by the Cochrane database of systematic reviews (CDBSR). Methodological consideration: All statements about hemophilia in the Cochrane Collaboration are based on evidence generated in randomized controlled clinical trials. Areas covered: There is a high degree of evidence that prophylaxis preserves joint function in children with hemophilia compared to on-demand treatment. Also, that recombinant factor VII activated (rFVIIa) and activated prothrombin complex concentrates (APPCs) have similar efficacy and safety. In patients with hemophilia or von Willebrand disease who undergo minor oral surgery or dental extractions, antifibrinolytic therapy has not been shown to be effective in the prevention of oral bleeding; the possible benefit of physical exercise in hemophilia remains unclear. The effectiveness and safety of the gene therapy have not been proven. Evidence suggests that prophylaxis with bypassing agents may be effective in reducing bleeding in hemophilic patients with inhibitor. Expert opinion: Hemophilia physicians should follow the recommendations of the CDBSR. PMID: 31610130 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research